Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JY231 in Relapsed/Refractory Neurologic Immune Disorders
NCT06797024Phase 1Recruiting
- Sponsor
- Tongji Hospital
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JY231 in Neuromyelitis Optica Spectrum Disorder (NMOSD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and 4 more, sponsored by Tongji Hospital. Primary endpoints: Incidence of adverse events (AE) after infusion at Month 24 and Maximal Tolerated Dose up to 28 days. Started Feb 2025; status: recruiting.
02
Drugs
JY231
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)myasthenia gravis (MG)chronic inflammatory demyelinating polyneuropathy (CIDP)idiopathic inflammatory myopathy (IIM)multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06797024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06797024.